Fusion’s Expanded Access Policy

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.

At this time, Fusion does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational products whenever possible. Clinical trials are designed, conducted, and monitored to ensure that the safety and effectiveness of investigational products are appropriately evaluated before the results from the trials are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.

You and your health care provider may learn more about our clinical trials by going to the pipeline section of our website, or visiting www.clinicaltrials.gov and searching for Fusion Pharmaceuticals.

If you are a health care provider who is interested in learning more about one of our investigational products, or a physician with questions about participation in one of our clinical trials, please submit a request to clinicaltrials@fusionpharma.com.  The company will acknowledge questions as soon as possible, usually within 10 business days of receipt.

If applicable, this website will be updated with hyperlinks to the relevant expanded access information on www.clinicaltrials.gov upon activation. Fusion reserves the right to revise this expanded access policy at any time.